Trevi’s Strategic Gambit: Targeting Chronic Cough with Clinical Might

NEW HAVEN, CT – June 17, 2026 – In the world of clinical-stage biotechs, a simple press release announcing conference attendance can often be overlooked. But for Trevi Therapeutics, the upcoming tour of its senior leadership across San Diego, Boston, and London is anything but routine. It represents a meticulously orchestrated strategic offensive, timed to capitalize on compelling clinical data and a newly fortified financial position. The company is not just presenting; it is making a definitive statement about its intention to dominate a therapeutic area that has long eluded a solution: chronic cough.

At the heart of this strategy is Haduvio™ (oral nalbuphine ER), an investigational therapy that has shown unprecedented success in clinical trials for a range of debilitating cough conditions. Trevi’s management will be leveraging this momentum at the BIO International Convention, the Leerink Partners Therapeutics Forum, and the ERS Cough Conference. This isn't just about sharing data; it's about signaling to investors, potential partners, and the medical community that a potential paradigm shift in respiratory treatment is on the horizon.

A Clinical Foundation Built on Robust Data

Trevi's confidence is not unfounded. It is built upon a bedrock of statistically significant clinical results from two key trials. For patients with idiopathic pulmonary fibrosis (IPF)—a fatal lung disease where up to 85% suffer from a relentless chronic cough—the Phase 2b CORAL trial was a watershed moment. The study demonstrated that Haduvio achieved a staggering 60.2% reduction in 24-hour cough frequency at its highest dose, a result that was not only statistically significant but also rapid, with effects seen as early as two weeks.

These results, published in the prestigious Journal of the American Medical Association (JAMA), lend a level of scientific validation that is crucial for a company at this stage. The therapy was also generally well-tolerated, with discontinuation rates due to side effects comparable to placebo—a critical factor for a drug intended for chronic use.

Similarly, in the Phase 2a RIVER trial for refractory chronic cough (RCC), a condition affecting 2-3 million Americans with no approved treatments, Haduvio delivered a 67% reduction in cough frequency from baseline. This dual success across different patient populations underscores the potential of Haduvio's unique mechanism of action. The drug functions as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors in both the central and peripheral nervous systems that regulate the cough reflex. This dual-action approach may be the key to its robust efficacy where other mechanisms have failed.

A Market Gasping for Relief

The commercial opportunity Trevi is targeting is immense, defined by profound unmet need. The U.S. alone has approximately 140,000 IPF patients and over 228,000 with other non-IPF interstitial lung diseases, with more than half of each group battling uncontrolled chronic cough. For these individuals, coughing can be an all-day ordeal, with some experiencing up to 1,500 coughs per day, leading to social isolation, depression, and a severely diminished quality of life. For IPF patients, this constant, violent coughing can even worsen their underlying disease and increase mortality risk.

This therapeutic void has not gone unnoticed. The race to develop a chronic cough treatment has seen major pharmaceutical players enter and stumble. Merck’s P2X3 antagonist, gefapixant, faced a second rejection from the FDA in 2023, highlighting the high regulatory bar and the difficulty of demonstrating a clear benefit-risk profile. This competitive context makes Trevi’s progress all the more significant. With Haduvio’s distinct mechanism and strong data, the company has a credible shot at becoming not only a "best-in-class" therapy but also a "first-in-class" approved treatment for chronic cough in IPF, a market where existing antifibrotic drugs offer no cough relief.

The Strategic Roadshow: Capitalizing on Momentum

Strong data alone does not guarantee success. It must be paired with shrewd financial management and strategic execution, an area where Trevi is demonstrating considerable foresight. An April 2026 public offering secured approximately $162 million in net proceeds, extending the company’s cash runway into 2030. This financial fortification is a powerful statement, assuring investors that Trevi is fully funded to execute its ambitious and expensive late-stage clinical program without near-term financial pressure.

This war chest provides the backdrop for the company's summer conference tour. Each stop is tailored to a specific strategic objective:

• BIO International Convention: A prime venue for business development, where CEO Jennifer Good and CCO Farrell Simon can engage with potential pharmaceutical partners for future commercialization and collaboration.
• Leerink Partners Therapeutics Forum: A direct line to the investment community. With CFO David Hastings in attendance, the goal is to translate clinical promise into a compelling financial narrative, attracting and retaining institutional capital.
• ERS Cough Conference: A scientific forum in London where CEO Good and CDO James Cassella, Ph.D., can engage with key opinion leaders, present their data to a specialist audience, and solidify Haduvio’s scientific credibility within the respiratory medicine community.

This multi-pronged approach demonstrates a mature understanding of how to build value around a clinical asset. It’s about creating a narrative of inevitability that resonates with scientists, doctors, and financiers alike.

Navigating the Final Hurdles

With a successful End-of-Phase 2 meeting with the FDA already complete, Trevi is now preparing to launch two pivotal Phase 3 trials for Haduvio in IPF chronic cough, with the first slated to begin by June 2026. The company will advance the 54 mg dose, which showed a powerful combination of efficacy and tolerability in the CORAL study. Furthermore, a human abuse potential study has suggested a favorable profile for Haduvio compared to other opioids, and the fact that its active ingredient, nalbuphine, is not currently scheduled by the DEA could provide a significant commercial and safety advantage upon approval.

Trevi Therapeutics stands at a critical inflection point where clinical success, financial stability, and strategic vision are converging. The company’s upcoming presentations are more than just an update; they are a declaration of intent to finally bring relief to millions of patients and, in doing so, capture a market that has been waiting for a breakthrough.